Vivo Bio Tech Ltd

(511509)

Vivo Bio Tech is a full service CRO that provides a range of drug development and discovery services tailored to the needs of global pharmaceutical and biotechnology companies in accordance with OECD AAALAC IND guidelines. With experienced and talented scientists, our services include In vitro and In vivo toxicity studies, pharmacological investigations, pharmacokinetics, toxicokinetic studies, gene synthesis, cloning, expression and purification of recombinant proteins and monoclonal antibodies. Additionally, we offer services for pharmacologic, toxicological and bioanalytical investigations for drug discovery and development, including bacterial reverse mutation assays, chromosomal aberration and micronucleus. Our Invivo Services group provides both nonregulatory and regulatory IND enabling preclinical development services as well as design and development of xenograft models for evaluation of anticancer agents. We have also partnered with Taconic for sourcing foundation and expansion colonies of animal models, in addition to beginning in-house breeding of Specific Pathogen Free rodents.

Share Price: ₹38.57 per share as on 22 Nov, 2024 04:01 PM
Market Capitalisation: ₹56.77Cr as of today
Revenue: ₹12.04Cr as on September 2024 (Q3 24)
Net Profit: ₹5.23Cr as on September 2024 (Q3 24)
Chairperson Name: K Sunder